Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 6, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is an observational study looking at patients with systemic amyloidosis, a condition that can cause heart problems, specifically cardiomyopathy. The researchers want to learn more about how this disease affects patients and gather information that can help improve treatment and care options.
To participate in this study, individuals must be at least 18 years old and either have been diagnosed with amyloidosis or carry a specific genetic mutation related to the condition, even if they don’t show symptoms yet. The study is currently recruiting participants of all genders, and there are no other specific exclusions. Those who join the study will provide informed consent, meaning they agree to participate after being fully informed about the trial. Participants can expect to share their health information, which will help researchers understand the disease better and potentially lead to new insights in managing systemic amyloidosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with amyloidosis or asymptomatic carriers of mutations in the transthyretin gene
- • minimum age of 18 years at the time of diagnosis
- • obtaining informed consent
- Exclusion Criteria:
- • nothing
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Simone Longhi, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported